-
Transcranial Magnetic Stimulation in Human Motor Recovery for Stroke and Spinal Cord Injury
Dylan J. Edwards, PhDDone
-
Optimizing TMS: Lessons from the world's largest TMS database
Eleanor Cole, MSc PhDDone
-
TMS Advances in Clinical Practice
Grant Hilary Brenner, MD, DFAPADone
-
Brain Monitoring Beyond the Laboratory: fNIRS Across Disciplines and Real-World Contexts
Hasan Ayaz, PhDDone
-
Coffee Break
Done
-
Poster Session
Done
-
Romain Duprat, PhD
Done
-
Registration
Done
-
Poster Session
Done
-
Signals of Emotion
Alana Campbell, PhDDone
A Novel Home-based Device for Combined Occipital and Trigeminal Afferent Stimulation to Treat Depression
KEYNOTE SPEAKER
Neuromodulation - Advancements and Refinements
4/16/26, 9:10 AM
-
4/16/26, 10:00 AM
(US/Eastern)
(50 minutes)
Linda L. Carpenter, MD
Professor of Psychiatry and Human Behavior
at Butler Hospital, Brown University
Linda L. Carpenter, MD
Professor of Psychiatry and Human Behavior
at Butler Hospital, Brown University
Linda L. Carpenter, MD, is Professor of Psychiatry at the Alpert Medical School of Brown University and Chief of the Mood Disorders Program at Butler Hospital. She directs the hospital’s TMS Clinic and Neuromodulation Research Facility, where her team conducts pioneering studies using brain stimulation techniques to advance treatment for depression and other disorders. Her research has focused on understanding the neurobiology of mood and anxiety disorders and the development of novel therapeutics, including TMS, tDCS, VNS, DBS, and other devices. She currently co-leads a two-site NIH-funded project developing an EEG-TMS method to determine optimal stimulation frequency for personalized TMS treatment of depression, and she recently completed a multisite randomized trial of a home-use neuromodulation device that stimulates external trigeminal and occipital branches for treatment-resistant major depression.
Patients with treatment-resistant major depressive disorder (MDD) have limited options for addressing their symptoms that have not responded to antidepressant medications. Neuromodulation therapies such as TMS, VNS, and ECT have demonstrated efficacy, but each has features that limit their accessibility or acceptability. External combined occipital and trigeminal afferent stimulation (eCOT-AS) is a novel approach to non-invasive neuromodulation for depression. Proliv Rx, a wearable, home-use headset device by Neurolief, delivers electrical pulses through 3 output channels and 6 surface electrodes acting concomitantly on peripheral branches of both the occipital and trigeminal nerves. A randomized, double-blind, sham-controlled, multicenter study recently investigated the efficacy and safety of an 8 week-course of self-administered daily (30-40 min/session) active or sham eCOT-AS therapy in 124 adults with MDD who failed to respond to antidepressants. The double-blind phase was followed by an 8-week active open label phase. In this presentation, the positive trial results will be presented and differences between ProlivRx and other currently marketed home-use devices for depression will reviewed. Discussion of the findings will highlight the potential role and position of eCOT-AS relative to currently available treatment options for treatment-resistant MDD.